Rationale for cholesterol lowering.
Evidence from research in five areas (epidemiology, experimental pathology, clinical medicine, clinical genetics, and clinical trials) provides the basis for current strategies for lowering cholesterol levels. Current interest in this field has been intensified by new information on the mechanisms of pathogenicity of cholesterol-rich plasma lipoproteins, by the results of clinical trials of cholesterol-lowering that demonstrate reduced rates of atherosclerosis progression as well as reduced incidence of clinical end points of atherosclerotic disease, and by the availability of new drugs and drug combinations that effectively lower the level of cholesterol-rich lipoproteins in the blood. Current research on the influence of certain species of triglyceride-rich lipoproteins and high-density lipoproteins on atherosclerosis and its complications has the potential to widen the scope of intervention strategies. Available evidence is, however, sufficient to warrant a broad-based effort to translate into clinical practice our ability to lower cholesterol.
Havel
R J
RJ
Cardiovascular Research Institute, University of California, San Francisco 94143-0130.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood*; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood
D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D002784:Cholesterol